• DDX23 Restricts SVA via Caspase-Mediated Apoptosis: Mechanis

  2026-06-17

  This study elucidates how DEAD-box helicase 23 (DDX23) restricts Senecavirus A (SVA) replication by targeting viral proteins for caspase-dependent degradation, while SVA counters with its 2B and 3A proteins to degrade DDX23. By pinpointing critical amino acid residues, the research details a molecular 'arms race' and highlights potential targets for antiviral intervention in swine virology.

• Tivozanib (AV-951): Selective VEGFR Inhibition in Oncology R

  2026-06-16

  Tivozanib (AV-951) is a potent and highly selective tyrosine kinase inhibitor targeting VEGFR-1, VEGFR-2, and VEGFR-3. It demonstrates superior anti-angiogenic efficacy and selectivity in renal cell carcinoma models compared to earlier TKIs. This article details its molecular mechanism, validated benchmarks, and workflow integration for advanced oncology research.

• Refining In Vitro Evaluation of Anti-Cancer Drug Responses

  2026-06-16

  Schwartz's dissertation challenges common in vitro drug testing by dissecting how anti-cancer agents influence both cell proliferation and death, rather than treating these outcomes interchangeably. The work advances experimental design and analysis, enabling more precise interpretation of angiogenesis inhibition and tumor growth modulation in cancer biology research.

• WP1066 in Cancer and Immune Metabolism: A JAK2/STAT3 Paradig

  2026-06-15

  Explore how WP1066, a potent JAK2/STAT3 inhibitor, advances both cancer research and immune metabolic modulation. This article unveils new insights into macrophage-driven tissue regeneration and practical experimental strategies.

• AZD3463 ALK/IGF1R Inhibitor: Workflow Optimization in Neurob

  2026-06-15

  AZD-3463 uniquely empowers neuroblastoma and ALK-driven cancer research with dual ALK/IGF1R pathway inhibition, high-affinity targeting—including resistance mutations—and robust combination therapy potential. This workflow-centric guide covers experimental setup, protocol parameters, and troubleshooting strategies to maximize reproducibility and translational impact.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-06-14

  Schwartz's dissertation introduces a nuanced comparison of cell proliferation and cell death metrics for in vitro anti-cancer drug evaluation. This methodological advance has important implications for the reproducibility and interpretation of tyrosine kinase inhibitor studies and supports more precise modeling of anti-angiogenic therapies.

• Potent Pyrimidine Inhibitors Target TSSK2 for Male Contracep

  2026-06-13

  This study identifies the first sub-100 nM pyrimidine and pyrrolopyrimidine inhibitors of testis-specific serine/threonine kinase 2 (TSSK2), a promising target for reversible male contraception. The findings establish new benchmarks for potency and selectivity in kinase inhibitor design, informing future contraceptive and kinase-targeted drug development.

• Morin: Applied Protocols and Innovations in Disease Modeling

  2026-06-12

  Morin, a high-purity natural flavonoid, stands apart for its dual role as a mitochondrial modulator and fluorescent probe. This guide translates breakthrough mechanistic findings into actionable workflows, troubleshooting, and advanced applications for metabolic disease, kidney injury, and ion detection research.

• Axitinib (AG 013736): Precision Tools for Angiogenesis Assay

  2026-06-12

  Axitinib (AG 013736) delivers unparalleled selectivity and reproducibility in angiogenesis inhibition and tumor xenograft research. This guide translates the latest in vitro evaluation frameworks and workflow enhancements into actionable protocols, arming cancer biology labs with advanced troubleshooting and data interpretation strategies.

• Eclipta–Hordeum Extract Delays Precocious Puberty in Danazol

  2026-06-11

  This study demonstrates that an Eclipta prostrata and Hordeum vulgare extract complex (EHEC) can effectively delay precocious puberty onset in rat models induced by Danazol or high-fat diet. By modulating the hypothalamic–pituitary–gonadal axis and attenuating GnRH expression, EHEC offers promising evidence for natural alternatives to current pharmacological interventions.

• HyperScribe Co-transcription mRNA Synthesis Kit Plus: Applie

  2026-06-11

  The HyperScribe Co-transcription mRNA Synthesis Kit Plus unlocks robust, high-yield ARCA-capped mRNA production with integrated poly(A) tails, streamlining demanding applications from RNA vaccine design to RNAi. Explore optimized protocols, advanced use-cases, and expert troubleshooting that set this kit apart in translational research.

• Ruxolitinib (INCB018424): Advanced Workflows in JAK-STAT Res

  2026-06-10

  Ruxolitinib (INCB018424) empowers high-resolution dissection of JAK-STAT signaling and immune remodeling in myeloproliferative disorder research. This guide translates recent breakthroughs in spectral flow cytometry and combination therapy into actionable protocols and troubleshooting strategies for advanced immunoprofiling and oncogenic JAK2 fusion studies.

• Anlotinib Hydrochloride: Optimizing Multi-Target Angiogenesi

  2026-06-10

  Anlotinib hydrochloride is revolutionizing angiogenesis and cancer research as a selective, high-potency multi-target tyrosine kinase inhibitor. This guide translates key preclinical breakthroughs into actionable protocols, advanced workflows, and troubleshooting strategies for robust, reproducible results.

• Targeted Amikacin Sulfate Delivery: A New Era for NTM Therap

  2026-06-09

  This article provides translational researchers with an in-depth, evidence-backed roadmap for leveraging Amikacin Sulfate in advanced non-tuberculous mycobacterial infection models. It synthesizes mechanistic insights, pivotal in vivo findings, and strategic considerations, with actionable guidance on protocol design and the translational potential of dendritic cell-mediated delivery.

• Pazopanib (GW-786034): Translational Insights for Targeted C

  2026-06-09

  Explore the advanced mechanisms and translational applications of Pazopanib (GW-786034) in cancer research. Discover unique insights into ATRX-deficient tumor models and practical assay optimization, setting this resource apart from standard protocol guides.

7426 records 11/496 page Previous Next First page 上5页 1112131415 下5页 Last page